The number that will follow infigratinib into every regulatory submission is +2.1 cm/year: the observed mean improvement in annualized height velocity over placebo that BridgeBio reported from the Phase 3 PROPEL 3 trial, published this week in the New England Journal of Medicine. For context, the adjusted mean difference in annualized growth velocity reported in vosoritide’s Phase 3 trial published in The Lancet was 1.57 cm/year over placebo at 52 weeks. BridgeBio is not shy about the comparison: PROPEL 3 reports the largest mean height velocity increase versus placebo recorded in any Phase 3 achondroplasia study to date, and that claim now carries the weight of NEJM peer review behind it.
The body proportionality result is arguably more clinically meaningful than the height velocity headline. In a pre-specified exploratory analysis of children under 8 years old, infigratinib produced a statistically significant improvement in the sitting height-to-standing height ratio versus placebo, an LS mean treatment difference of -0.05 (p less than 0.05). No prior Phase 3 achondroplasia trial had achieved a statistically significant placebo-controlled proportionality result. The arm span data presented simultaneously at ICCBH extended that picture: a +0.37 SD improvement over placebo (p less than 0.0001), also described as the first statistically significant arm span result from a controlled achondroplasia trial. Taken together, these findings reframe infigratinib’s profile from a pure growth-rate drug to one with documented effects on skeletal morphology, which matters enormously for labeling negotiations and payer arguments about functional benefit.
The safety read at 52 weeks is clean in a way that will draw scrutiny precisely because FGFR inhibition carries known off-target risks. There were no discontinuations related to study drug, no serious adverse events attributed to treatment, and only three cases of hyperphosphatemia, all mild, transient, and asymptomatic. Critically, no retinal or corneal adverse events appeared, the signal most associated with FGFR1 and FGFR2 inhibition. Infigratinib’s selectivity for FGFR3 is central to BridgeBio’s mechanistic argument, and 52 weeks of clean ocular data is the first meaningful evidence that selectivity translates to clinical tolerability in this pediatric population. Breakthrough Therapy Designation, granted in September 2024, already signaled FDA’s interest in this mechanistic distinction.
BridgeBio plans to submit its NDA in Q3 2026, with a U.S. launch targeted for early to mid 2027. The regulatory path now runs through FDA’s review clock, and the single number worth watching from here is the label’s approved age range. Vosoritide‘s initial approval covered children five and older; PROPEL 3 enrolled children down to age 3, and how FDA bounds the infigratinib indication will determine the breadth of the commercial opportunity and the competitive differentiation from the moment of approval.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
